NIDA Director, Nora Volkow talks about the need for treatments for stimulant and polysubstance use and overdoses during the 152 Meeting of the National Advisory Council on Drug Abuse
Updated: 6 days ago
Cambridge, MA | March 2026
During the 152 meeting of the National Advisory Council on Drug Abuse, NIDA Director, Nora Volkow, discusses the challenges to treatment and overdoses, particularly surrounding stimulants and polysubstance use disorder.
Dr. Volkow highlights that there are currently no FDA approved medication for stimulant use disorder, nor is there treatment available for polysubstance use. She also notes that while opioid deaths are decreasing, stimulant deaths are increasing, equaling out the fatalities by drug class.
About Clear Scientific
Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland.
Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body. Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals.
About CS-1103
CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. Clear Scientific is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of drug fatalities in the US. The Company’s pipeline includes indications in substance use disorder, central nervous system (CNS) and metabolic diseases amongst others. CS-1103 is investigational and has not been approved by any health authority.
For more information, visit https://www.clearsci.com.


Comments